Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
← catalyst calendarNCT07578649 · readout in 1,017 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT).
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
600estimated
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-10-09 | estimated | When the study began enrolling |
| Primary completion | 2029-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-01-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Endometrial Neoplasms
- Endometrial Cancer
Interventions
- Biological: PF-08634404
- Biological: Pembrolizumab — also filed as keytruda
- Drug: Standard of Care Chemotherapy
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS) using RECIST v1.1 as assessed by Blinded Independent Central Review (BICR)
measured Approximately 36 months
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed